Monitoring potential adverse effects of new Alzheimer's medicines is an essential part of patient care and drug research. A new article in RadioGraphics, a journal of the Radiological Society of North America (RSNA), investigates the use of monoclonal antibody therapies for the treatment of Alzheimer's disease and warns physicians about a potential side effect: amyloid-related imaging abnormalities (ARIA). Alzheimer's disease is a gradual, irreversible brain illness that causes memory and cognitive function to deteriorate over time. It is the most common type of dementia in the world. While prior treatments focused on symptoms of Alzheimer's disease, recent approvals of monoclonal